By George Ongkojoyo 
A collaborative research effort led by the Biocenter of Julius-Maximilians-Universität Würzburg (JMU), in partnership with the Wellcome Sanger Institute in Cambridge, has marked a transformative milestone in the field of pediatric oncology. By analyzing one of the world’s most comprehensive collections of kidney tumor samples, the research team has successfully mapped the hereditary landscape of Wilms tumors, the most common form of kidney cancer in children. The study, recently published in the prestigious journal Genome Medicine, provides a molecular blueprint that clarifies why certain children are predisposed to these malignant growths and offers a new framework for clinical monitoring and genetic counseling.
Wilms tumors, or nephroblastomas, primarily affect children under the age of five. While modern multi-modal therapies have pushed survival rates to nearly 90 percent, the underlying genetic causes have remained partially obscured for decades, particularly in cases involving bilateral tumors—those affecting both kidneys—or familial clusters. The JMU-led study utilized the German Wilms tumor biobank to perform a systematic genomic analysis of a large cohort, ultimately identifying the genetic or epigenetic triggers in over 90 percent of the high-risk cases examined.
The Scientific Foundation: Three Decades of the Wilms Tumor Biobank
The cornerstone of this breakthrough is the Wilms tumor biobank located at the JMU Biocenter. This repository represents nearly 30 years of meticulous data collection and sample preservation, spanning from 1994 to 2022. During this period, samples from approximately 1,800 children were integrated into the German Wilms tumor study.
The researchers focused their deep-dive analysis on two specific subgroups that strongly suggest a genetic predisposition: 20 cases of familial tumors, where the disease appeared in siblings or parents, and 109 cases of bilateral tumors. Bilateral cases are particularly significant in oncology research because the occurrence of primary tumors in both kidneys simultaneously suggests that the "first hit" or initial genetic mutation is likely present in all cells of the patient’s body (the germline), rather than occurring sporadically in a single kidney cell.
Dr. Jenny Wegert, the study’s lead author and a researcher at the Department of Developmental Biochemistry at JMU, noted that the scale and duration of the biobank provided a "scientific treasure" that allowed the team to see patterns that smaller studies could not detect. By applying advanced sequencing technologies to these decades-old samples, the team achieved a resolution of genetic data that was previously impossible.
Molecular Mechanisms: Validating the Two-Hit Hypothesis
A central achievement of the study is the molecular confirmation of the "two-hit hypothesis," a theory first proposed by geneticist Alfred Knudson in 1971. Knudson suggested that for a tumor suppressor gene to be inactivated and lead to cancer, both copies of the gene (one from each parent) must be damaged. In hereditary cases, the first "hit" is inherited, while the second occurs during the child’s development.
The JMU and Sanger Institute researchers demonstrated this progression with unprecedented detail. The most frequent driver identified was the mutation of the WT1 (Wilms Tumor 1) gene. This gene is a critical tumor suppressor that normally regulates kidney and gonadal development.
The study outlines a stereotypical three-step progression toward malignancy:
- Germline Inactivation: One copy of the WT1 gene is inactivated in all body cells. This stage does not yet produce a tumor but places the child at high risk for kidney failure and, in males, genitourinary malformations.
- Epigenetic Activation: The second copy of the WT1 gene in the kidney cells fails, and simultaneously, the growth factor IGF2 (Insulin-like Growth Factor 2) is activated. This combination triggers the formation of "pre-neoplastic" lesions or tumor precursors.
- Malignant Transformation: The final step involves the activation of the WNT signaling pathway. This pathway is a fundamental mechanism that controls cell growth and differentiation. When overstimulated in the presence of WT1 loss and IGF2 activation, it drives the rapid development of a malignant Wilms tumor.
Genomic Imprinting and the Discovery of Mosaicism
One of the most surprising findings of the study involved the role of genomic imprinting. In roughly one-third of the children studied, the researchers found no classic hereditary mutations in their DNA sequence. Instead, they discovered a disturbance in the "imprinting" of the IGF2 gene.
Genomic imprinting is an epigenetic process where certain genes are expressed in a parent-of-origin-specific manner. In the case of IGF2, a normal cell only expresses the copy inherited from the father. If this regulation fails—a condition known as "loss of imprinting"—the cell begins to express both copies, leading to an overdose of growth signals.
Crucially, the researchers identified that many of these children exhibited "mosaicism." This means that the child’s body is a mixture of healthy cells and cells with the IGF2 imprinting error. Because this error often occurs during embryonic development rather than being passed down from a parent, it is not "hereditary" in the traditional sense.
"This distinction is vital for families," Dr. Wegert explained. "If the predisposition is due to an imprinting error rather than a germline mutation, there is no increased risk for siblings, and the patient will not pass the predisposition to their own future children."
Supporting Data and Statistical Context
To understand the impact of this study, it is necessary to view it within the broader context of pediatric oncology statistics. Wilms tumors account for approximately 95 percent of all kidney cancers in children. In the United States and Europe, the incidence rate is roughly 8 to 10 cases per million children under the age of 15.
The study’s findings on WT1 mutations are particularly impactful because these mutations are often associated with Denys-Drash syndrome and Frasier syndrome—conditions that lead to early-onset renal failure. Historically, about 10 to 15 percent of Wilms tumor patients have an underlying genetic syndrome. The JMU study suggests that the actual percentage of patients with some form of genetic or epigenetic predisposition may be higher than previously estimated, particularly when considering mosaicism.
By identifying the underlying cause in over 90 percent of familial and bilateral cases, the research team has set a new benchmark for diagnostic success. Prior to this, a significant portion of bilateral Wilms tumor cases remained "genetically unexplained," leaving families with uncertainty regarding the risk to other children.
Clinical Implications: A Call for Universal Genetic Screening
The findings have immediate and profound implications for clinical practice. Professor Manfred Gessler, Chair of Developmental Biochemistry and the study’s lead, emphasizes that the presence of a hereditary component changes the entire management strategy for a patient.
"Our findings demonstrate that a significant proportion of childhood kidney tumors have a genetic root," Professor Gessler stated. "This leads to a clear clinical recommendation: broad molecular testing of both blood and tumor samples should be standard for young patients."
The rationale for universal screening is three-fold:
- Risk Assessment for Siblings: Identifying a true germline mutation allows parents to seek genetic counseling and early screening for other children.
- Secondary Tumor Prevention: Patients with certain germline mutations are at a higher risk for developing secondary tumors later in life or experiencing early-onset chronic kidney disease. Early identification allows for nephron-sparing surgery and specialized follow-up care.
- Personalized Monitoring: Children identified with IGF2 imprinting disorders or WT1 mutations require more frequent ultrasound monitoring to detect potential new tumors in the remaining kidney tissue or the contralateral kidney.
Broader Impact and Future Outlook in Pediatric Oncology
The collaboration between the JMU Biocenter and the Wellcome Sanger Institute highlights the power of international cooperation in rare disease research. By combining the vast sample resources of the German biobank with the advanced genomic sequencing capabilities of the Sanger Institute, the team was able to provide answers that had eluded the scientific community for decades.
This research also contributes to the growing field of "epigenetic medicine." By highlighting how non-hereditary "imprinting" errors can trigger cancer, the study opens the door for future therapies that might target these epigenetic marks rather than the DNA sequence itself.
Furthermore, the study provides a roadmap for researching other childhood cancers. The "two-hit" mechanism and the role of developmental signaling pathways like WNT are common themes in pediatric oncology. The methodology used here—linking long-term biobank samples with comprehensive germline and somatic sequencing—serves as a model for deciphering the origins of other rare pediatric malignancies.
As genetic testing becomes more accessible and affordable, the integration of these findings into standard hospital protocols is expected to improve the long-term quality of life for survivors. While the cure rate for Wilms tumors is already high, the focus is now shifting toward "precision survivorship"—ensuring that children who survive cancer do not face a lifetime of complications due to undetected genetic predispositions.
The JMU and Sanger Institute study stands as a testament to the importance of long-term scientific investment. The 30-year effort to maintain the Wilms tumor biobank has finally yielded a molecular key that promises to transform the lives of young patients and their families, moving the needle from reactive treatment to proactive, genetically-informed care.
